VTGN Quote, Financials, Valuation and Earnings

GeoVax Labs, Inc. has a net margin of -7525.97% compared to Vistagen Therapeutics, Inc.'s net margin of -630.04%. Vistagen Therapeutics, Inc.'s return on equity of -76.57% beat GeoVax Labs, Inc.'s return on equity of -433.69%.

Vistagen Therapeutics, Inc. has a consensus price target of $14.50, signalling upside risk potential of 288.74%. On the other hand GeoVax Labs, Inc. has an analysts' consensus of $9.63 which suggests that it could grow by 2409.12%. Given that GeoVax Labs, Inc. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Vistagen Therapeutics, Inc..

Vistagen Therapeutics, Inc. has a beta of 0.561, which suggesting that the stock is 43.86% less volatile than S&P 500. In comparison GeoVax Labs, Inc. has a beta of 3.638, suggesting its more volatile than the S&P 500 by 263.848%.

Vistagen Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeoVax Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics, Inc. pays -- of its earnings as a dividend. GeoVax Labs, Inc. pays out -- of its earnings as a dividend.

Vistagen Therapeutics, Inc. quarterly revenues are $258K, which are larger than GeoVax Labs, Inc. quarterly revenues of --. Vistagen Therapeutics, Inc.'s net income of -$19.4M is lower than GeoVax Labs, Inc.'s net income of -$6.3M. Notably, Vistagen Therapeutics, Inc.'s price-to-earnings ratio is -- while GeoVax Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics, Inc. is 130.92x versus 1.66x for GeoVax Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Omeros Corp. has a net margin of -7525.97% compared to Vistagen Therapeutics, Inc.'s net margin of --. Vistagen Therapeutics, Inc.'s return on equity of -76.57% beat Omeros Corp.'s return on equity of --.

Vistagen Therapeutics, Inc. has a consensus price target of $14.50, signalling upside risk potential of 288.74%. On the other hand Omeros Corp. has an analysts' consensus of $28.00 which suggests that it could grow by 153.85%. Given that Vistagen Therapeutics, Inc. has higher upside potential than Omeros Corp., analysts believe Vistagen Therapeutics, Inc. is more attractive than Omeros Corp..

Vistagen Therapeutics, Inc. has a beta of 0.561, which suggesting that the stock is 43.86% less volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.485, suggesting its more volatile than the S&P 500 by 148.518%.

Vistagen Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics, Inc. pays -- of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend.

Vistagen Therapeutics, Inc. quarterly revenues are $258K, which are larger than Omeros Corp. quarterly revenues of --. Vistagen Therapeutics, Inc.'s net income of -$19.4M is higher than Omeros Corp.'s net income of -$21.2M. Notably, Vistagen Therapeutics, Inc.'s price-to-earnings ratio is -- while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics, Inc. is 130.92x versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of -7525.97% compared to Vistagen Therapeutics, Inc.'s net margin of -40.15%. Vistagen Therapeutics, Inc.'s return on equity of -76.57% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Vistagen Therapeutics, Inc. has a consensus price target of $14.50, signalling upside risk potential of 288.74%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 122.96%. Given that Vistagen Therapeutics, Inc. has higher upside potential than Vanda Pharmaceuticals, Inc., analysts believe Vistagen Therapeutics, Inc. is more attractive than Vanda Pharmaceuticals, Inc..

Vistagen Therapeutics, Inc. has a beta of 0.561, which suggesting that the stock is 43.86% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.

Vistagen Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Vistagen Therapeutics, Inc. quarterly revenues are $258K, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Vistagen Therapeutics, Inc.'s net income of -$19.4M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Vistagen Therapeutics, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics, Inc. is 130.92x versus 1.46x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of -7525.97% compared to Vistagen Therapeutics, Inc.'s net margin of 52.48%. Vistagen Therapeutics, Inc.'s return on equity of -76.57% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Vistagen Therapeutics, Inc. has a consensus price target of $14.50, signalling upside risk potential of 288.74%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $70.67 which suggests that it could grow by 127.96%. Given that Vistagen Therapeutics, Inc. has higher upside potential than XOMA Royalty Corp., analysts believe Vistagen Therapeutics, Inc. is more attractive than XOMA Royalty Corp..

Vistagen Therapeutics, Inc. has a beta of 0.561, which suggesting that the stock is 43.86% less volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.919%.

Vistagen Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Vistagen Therapeutics, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vistagen Therapeutics, Inc. quarterly revenues are $258K, which are smaller than XOMA Royalty Corp. quarterly revenues of $9.4M. Vistagen Therapeutics, Inc.'s net income of -$19.4M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Vistagen Therapeutics, Inc.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 41.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics, Inc. is 130.92x versus 10.78x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.